Hyloris Pharmaceuticals SA Overview
Hyloris is a Liège-based specialty pharmaceutical group that creates "value-added medicines" by reformulating, repurposing and re-registering established molecules, primarily via the US FDA 505(b)(2) pathway and its European equivalents, and increasingly through selected, risk-mitigated new chemical entities. Its model is asset-light: development is outsourced to CMOs and CROs, and commercialisation is almost entirely partnered, with Hyloris capturing royalties, profit shares and milestones. Four products are now commercialised through partners — Maxigesic® IV (Combogesic® IV in the US), Sotalol IV, Podofilox Gel and Tranexamic Acid IV RTU — and the pipeline exceeds 30 products and candidates organised into "Core Drivers", "Mavericks" and "Promising Seeds". The company targets a development cost below EUR 7M per product over up to seven years. Revenue remains small (EUR 7.2M in FY2025) and loss-making, governance has been under regulatory scrutiny since 2024, and liquidity is tight (EUR 8.7M cash at 30 June 2026), making partnering execution the central value driver.
Company's own description
In its FY2025 and H1 2026 regulated releases, Hyloris describes itself as a specialty pharma group focused on reinventing and optimising existing medications through reformulation and repurposing to address healthcare needs for patients, healthcare professionals and payers. It emphasises leveraging established regulatory pathways (FDA 505(b)(2) and equivalents) for molecules whose safety and efficacy are already established, which it argues reduces clinical and regulatory burden, shortens timelines and lowers cost and risk. Since 2026 its boilerplate has added "smart NCE developments" to the description, reflecting in-licensed new chemical entities such as HY-094 (IV iron), Suramin IV and Methanobactin (HY-106). The company also states a targeted time-to-market of seven years at an average cost of EUR 7M per product (non-inflation adjusted) (H1 2026 release).
Business model
Hyloris operates a hub-and-partner model:
Sourcing: products are originated internally or in-licensed from academic institutions, small biotechs and development partners (e.g., AFT Pharmaceuticals, API, Vaneltix, Pleco Therapeutics, Purna/FHP BV, RedHill Biopharma, ArborMed, Wake Forest University, Kuvatris Therapeutics).
Development: formulation and analytical work partly in-house (in-house lab at LégiaPark built 2022–2023), with manufacturing at CMOs/CDMOs and clinical studies run via CROs.
Commercialisation: almost entirely out-licensed to regional partners (Hikma in the US for Maxigesic IV via AFT; AltaThera for Sotalol IV; Padagis for Podofilox Gel; Avenacy for TXA RTU US; Orion in Europe for TXA RTU and Pantoprazole IV RTU; Rosemont for US Valacyclovir and Atomoxetine oral liquids; numerous others). The company's stated strategic objective (FY2024 release) is to capture a significant share of net product margin realised by partners, preferring in-market sales or profit participation over upfront fees, and partnering near regulatory submission.
US cardiovascular strategy: historically, Hyloris planned to build its own US hospital sales force for IV cardiovascular products (IPO use of proceeds). Since 2024 it has been evaluating licensing, joint ventures or other partnerships for this portfolio; defining this "go-forward commercialisation strategy" remains a key 2026 priority (H1 2026 release).
Revenue model
| Revenue stream | Description | FY2025 (EUR K) | Share of FY2025 revenue |
|---|---|---|---|
| Royalties | Sales-based royalties/profit share from Maxigesic IV, Sotalol IV, Podofilox Gel | 5,649 | 78.4% |
| Milestones | Upfronts, regulatory and commercial milestones from out-licensing | 1,353 | 18.8% |
| Product sales | Direct supply of TXA RTU to partner (first in 2025) | 205 | 2.8% |
| Total revenue | — | 7,207 | 100% |
| Other operating income | Grants, Belgian R&D tax credits, other operational items (outside revenue) | 1,626 | — |
Source: Hyloris Consolidated Results 2025 (26 March 2026). The mix is therefore licensing/royalty-dominated (~97% of revenue) with a nascent product-supply component; there is no subscription or service revenue of note (historically small IP/regulatory service income to partners was reported in FY2022).
Value-chain position, customers and end-markets
Hyloris sits between molecule owners/academic inventors and commercial pharma companies: it adds formulation IP, regulatory dossiers and clinical bridging data, then hands off to partners who own sales, distribution and often manufacturing supply. Its direct customers are therefore pharmaceutical licensees; ultimate end-users are hospitals (IV analgesia, IV cardiovascular, IV hemostasis, IV PPI), specialists (cardiology, urology, gynaecology, dermatology, ADHD/paediatrics), dentists (XTRAZA, EU only now), and, via HY-095, the veterinary (equine) market.
End-markets served: hospital acute pain (non-opioid analgesia), cardiovascular (atrial fibrillation, heart failure, acute coronary syndrome), infectious disease (herpes viruses, HPV warts, vulvovaginal infections, skin infections), haemostasis, gastroenterology (acid-related disorders), CNS (ADHD), urology (IC/BPS), haematology (iron deficiency anaemia), rare diseases (Wilson's disease, rare inherited skin disorder, hypophosphatemia), oncology (AML adjunct), neglected tropical disease (human African trypanosomiasis), and animal health.
Independent characterisation
Hyloris is best understood as a micro-cap, pre-profit, royalty-aggregation development company rather than an operating pharma business. Its 30+ asset count is broad relative to its ~54 staff and ~EUR 15–16M annual operating expense base, which implies thin resourcing per program and heavy reliance on partners and CMOs; this is visible in repeated CMO-driven delays (Metolazone IV, Valacyclovir CRL, Aspirin IV API sourcing, Suramin IV). Its royalty base is real but small and concentrated in three to four products. Equity value is largely a function of (i) US launch trajectory of Combogesic IV and Sotalol IV, (ii) out-licensing of the cardiovascular portfolio (Dofetilide IV, Aspirin IV, HY-074, Metolazone IV, Milrinone ER), and (iii) binary optionality in NCE assets (HY-094, Suramin IV PRV). Governance history (FSMA warning, trading suspension, restatement, auditor qualifications, and an authorities' site visit in October 2026) materially affects its cost of capital.
Strategy
Stated strategy themes (latest releases)
Reinvent existing medicines plus "smart NCEs": leverage 505(b)(2)-type pathways for de-risked development; selectively add NCEs with clinical validation (HY-094, Suramin IV, Methanobactin).
Development discipline: target average development cost <EUR 7M per product and time-to-market ≤7 years (selection criteria reiterated FY2024 and H1 2026).
Three-tier portfolio management (2026): Core Drivers (predictable, capital-efficient near/medium-term value, including commercialised products), Mavericks (high-potential, clinically supported), Promising Seeds (earlier-stage optionality). Pruning of sub-scale programs (HY-075, HY-091, XTRAZA US).
Partner-led commercialisation: capture a significant share of partner net margin; partner near submission; prefer profit participation over upfronts.
US cardiovascular route-to-market: define go-forward strategy (licensing, JV or other partnership) — the single most important open strategic decision.
Governance: "disciplined execution and good governance" is now explicit in outlook language (H1 2026).
Strategic initiatives — last 24 months
| Initiative | Date | Description |
|---|---|---|
| 30-asset portfolio target | Achieved Dec 2025 | Six new candidates added in 2025 (Pantoprazole IV RTU, Ondansetron ER, HY-094, Suramin IV, Methanobactin, HY-098) |
| Eight out-licensing deals in 2025 | 2,025 | Valacyclovir (AFT, QliniQ), XTRAZA (Colonis, AFT, Huons), TXA RTU (Orion), Atomoxetine (Rosemont), HY-094 China (Grand Life Sciences) |
| Governance reinforcement | Jul 2024–Nov 2025 | Communication policy (Aug 2024), external governance review, written compliance policies, board approval flows for regulated communications, Product Selection Committee |
| 10-year strategic business plan | Board-approved Dec 2025; updated 2026 | Reflects revised commercial timing and R&D/G&A spend (H1 2026 release) |
| Portfolio review | H1 2026 | Discontinued HY-075, HY-091, XTRAZA US Phase 3 |
| Euronext Securities CSD migration | 14 Oct 2026 | First Belgium-headquartered issuer to adopt Euronext Securities' new European CSD model (non-regulated release) |
| ESOP Warrant Plan 2026 | Mar 2026 | 250,000 warrants for retention/alignment |
| Sustainability | 2022 onward | ESG objectives in Annual Report 2022; ESG chapter in Annual Reports 2024/2025; LégiaPark HQ move framed around sustainability and employee well-being |
Cost programs with quantified targets: none publicly announced beyond R&D phasing flexibility.
Management guidance and medium-term targets
Remainder of 2026 (H1 2026 release): regulatory submissions for Aspirin IV and Dofetilide IV in H2 2026; advance Alenura (End-of-Phase 2), HY-094 (Phase 3), Metolazone IV, Milrinone ER; define US cardiovascular strategy.
Earlier guidance (FY2024 release): up to nine product filings in 2025–2026 (Valacyclovir ex-US, Dofetilide IV, Atomoxetine, Aspirin IV, XTRAZA, Phosphate oral liquid, Metolazone IV, HY-074, Ondansetron ER). By October 2026, Valacyclovir (US, CRL) and Atomoxetine (US) have been filed; XTRAZA US is discontinued; Dofetilide and Aspirin slipped to H2 2026.
Financial targets: no quantified revenue or profitability guidance issued. Analysts (two covering, per Simply Wall St) had forecast break-even around 2026–2027 — not company guidance.
Products & Services
Organised per the company's 2026 Strategic Focus Groups (company product portfolio page, accessed October 2026; FY2025 and H1 2026 releases). Pricing models for individual products are not publicly disclosed; Hyloris earns royalties/profit shares/milestones from partners.
Core Drivers — commercialised products
| Product | Type | Description & key specs | Target customer / indication | Partner(s) | Status / year | IP |
|---|---|---|---|---|---|---|
| Maxigesic® IV (Combogesic® IV in US) | Reformulation (fixed-dose combo) | IV paracetamol 1,000 mg + ibuprofen 300 mg; non-opioid | Hospital acute/post-operative pain and fever | AFT Pharmaceuticals (worldwide co-development partner; Hyloris receives substantial minority share of AFT's margin); Hikma (US); Chengdu Tongde (China, Jul 2026); MIKASASEIYAKU (Japan, Sep 2026); Halex Istar (Brazil); nine-country European partner (2023) | Licensed >100 countries, approved >50, marketed >30; EU launch 2021; FDA approval Oct 2023; US launch Feb 2024; CMS permanent J-code effective 1 Oct 2024 | US patents expiring Jul 2035–Aug 2036 (formulation) and Jun 2039 (manufacturing); additional EU patents granted 2025 |
| Sotalol IV | Reformulation | IV formulation of established antiarrhythmic enabling IV loading, potentially reducing initiation hospitalisation to ~1 day | Hospital cardiology: AF/flutter rhythm maintenance; life-threatening ventricular arrhythmias | AltaThera (US commercialisation; license terminated but perpetual survival per Sept 2024 arbitration, royalties continue) | FDA-approved, US commercial | Formulation patents referenced through 2034 |
| Podofilox Gel 0.5% | High-barrier generic | First US generic of Condylox Gel | External genital/perianal warts (HPV) | Padagis US | FDA ANDA approval Dec 2023; launched Dec 2023; stock-out Q4 2025; back on market Q2 2026 | Belgian manufacturing-process patent |
| Tranexamic Acid IV RTU | High-barrier generic (US) / value-added (EU) | Ready-to-use 10 mg/mL, 100 mL vials; no reconstitution/dilution | Hospital haemostasis (labelled for haemophilia dental extraction; widely used for bleeding) | Avenacy (US, profit share); Orion (key European markets, Oct 2025); South Korean distributor terminated | FDA ANDA approval Jun 2025; US and Switzerland launch H1 2026; EU registrations ongoing | US patent to 2 Dec 2039; BE patent to 17 Jun 2039 |
Core Drivers — late-stage pipeline
| Product | Type | Description | Indication | Partner(s) | Status (Oct 2026) | IP |
|---|---|---|---|---|---|---|
| Valacyclovir Oral Suspension (ex HY-029) | Reformulation | Taste-masked, room-temperature-stable powder for suspension | Herpes zoster, cold sores, genital herpes, chickenpox (paediatric/dysphagia) | Rosemont (US), AFT (Canada, Australia, NZ), QliniQ (Netherlands); rights also in major EU markets, Mexico, China, South Korea, GCC | US NDA filed Dec 2024; FDA CRL (Feb 2026) on Greek CDMO inspection, no product-specific deficiencies; second source being qualified; launch may slip into 2027; EU procedures ongoing | US patents 2035–2036; pending to 2045 |
| Atomoxetine Oral Liquid | Reformulation | Taste-masked oral solution for weight-based titration | ADHD (paediatric) | Rosemont (US, Dec 2025); Canada licensee (2023); AFT (Australia/NZ, profit share) | Positive US study Jul 2025; NDA filed early 2026 by Rosemont (regulatory milestone recognised H1 2026); EU study enrolment completed Q1 2026 | Protection potentially to 2044 |
| Dofetilide IV | Reformulation | First IV dofetilide; IV loading could cut ≥3-day hospital initiation to ~1 day | AF/atrial flutter | US partner not yet announced | Positive pivotal (Mar 2025); FDA meeting Feb 2026 confirmed strategy; submission slipped from Q2 2026 to H2 2026 | Granted patents 2039–2043 |
| Aspirin IV | Reformulation | IV acetylsalicylic acid; faster onset vs oral | ACS / emergency cardiac events | Not yet partnered | Positive pivotal (Nov 2025); FDA alignment; US submission planned H2 2026; EU submissions envisaged | US patents 2038–2039 |
| HY-074 | Reformulation | IV formulation of a widely used oral antiplatelet | ACS | Not yet partnered | Registration batches produced; pivotal trial planned 2026 | Applications, expiry 2043–2044 |
| Metolazone IV | Reformulation | First injectable metolazone (lyophilised) | Acute decompensated heart failure / oedema | Not yet partnered | Registration batches initiated after CMO delays; clinical completion anticipated 2026 | Applications, expiry 2044 |
| Pantoprazole IV RTU | Reformulation | Directly injectable, storage-stable liquid PPI replacing lyophilised vials | GERD with erosive oesophagitis, hypersecretory conditions (hospital) | Orion (EU, UK, Switzerland, Norway; Jan 2026; upfront received H1 2026) | Formulation/registration batches in preparation; launch targeted 2028 | Applications, expiry 2045 |
| Phosphate Oral Liquid (HY-088) | Reformulation | Standardised ready-to-use oral phosphate | Hypophosphatemia | QliniQ retains NL/ME/developing-country rights | Registration batches complete; first European filing planned late H1 2026 (completion not confirmed in H1 2026 release) | Applications, expiry 2045–2046 |
| Ondansetron ER | Reformulation | Once-daily bimodal IR/ER oral ondansetron | CINV, RINV, PONV | In-licensed from RedHill Biopharma (rights ex-North America) | Late-stage; market entry targeted 2028 (FY2024 release) | Confidential |
| XTRAZA® (TXA oromucosal solution, ex HY-004) | Repurposing | Tranexamic acid oral rinse | Dental bleeding in anticoagulated patients | Colonis (UK), AFT (Canada, Australia, NZ, South Korea, Singapore, Hong Kong), Huons (South Korea) | US Phase 3 discontinued in 2026 despite IDMC recommendation to continue (IRR below target); scope reduced to EU | US patents to 2039 |
| Fusidic Acid cream 2% | High-barrier generic | Generic of Fucidin cream | Bacterial skin infections | — | Canadian submission expected 2026 | None assumed |
Mavericks — high-potential, clinically supported
| Product | Type | Description | Indication | Partner(s) | Status | IP / designations |
|---|---|---|---|---|---|---|
| HY-094 (IV Iron, NCE) | NCE | Next-generation IV iron with potential single-infusion dosing | Iron deficiency anaemia | Co-developed with AFT (global); Grand Life Sciences Group (China license, Oct 2025) | Phase 2b complete; IND clearance for Phase 3 obtained H1 2026 | Exclusive global human-use license; patent applications |
| Milrinone ER | Repurposing | Twice-daily oral ER milrinone | Right heart failure in LVAD patients | API (cardiovascular development partner — royalty arrangements disclosed) | Human Phase 1 PK started H1 2026 | Priority application 2025 (expiry 2046 if granted); FDA Orphan Drug Designation |
| Miconazole DB (NCE) | NCE/combination | Dual-action vaginal cream (miconazole + domiphen bromide) | VVC and bacterial vaginosis | FHP BV / Purna Female Healthcare | Phase 2 dose-finding in VVC complete; exploratory BV (Gardnerella) trial in preparation | IP to 2038, 2044, 2045 |
| Suramin IV (NCE in US) | NCE (first FDA approval of suramin) | Standardised IV suramin | T.b. rhodesiense human African trypanosomiasis; potential follow-on autism spectrum disorder | Kuvatris Therapeutics (Hyloris: just under 20% equity, slightly >50% of PRV net proceeds, sales royalties) | Phase 3 (Africa) delayed by manufacturer issues; ASD Phase 2 completed (by partner) | FDA Orphan Drug Designation; tropical disease PRV eligibility |
| Alenura™ | Repurposing | Ready-to-use intravesical alkalinised lidocaine + heparin | IC/BPS acute pain flares | Vaneltix | Phase 2 (Alenura-111, 4-arm, US/Canada) enrolment completed H1 2026; End-of-Phase 2 meeting targeted H2 2026 | Patents to 2038 |
Promising Seeds — early stage
| Product | Type | Description | Indication | Partner(s) | Status |
|---|---|---|---|---|---|
| HY-083 | NCE track | Intranasal TRPV1 agonist spray | Idiopathic rhinitis | Walloon Region grant (EUR 1M) | NCE candidates synthesised; potency in assays |
| HY-095 | Reformulation (veterinary) | Long-acting injectable PPI | Equine Gastric Ulcer Syndrome | External formulation partner | First horse prototype testing 2025; further testing 2026 |
| HY-098 | Repurposing | Topical form of an established systemic drug | Rare inherited inflammatory skin disorder | Wake Forest University School of Medicine (option) | Exploratory trial may start 2026 |
| HY-089 (also referenced as HY-090 in earlier releases) | Repurposing | Locally acting oral solution | Burning mouth syndrome | AFT (equal partnership) | Two pre-prototypes |
| HY-086 (PTX-252) | NCE | Chelating adjunct to chemotherapy | AML (plus SCLC exploratory) | Pleco Therapeutics | Formulation complete; Phase 1 preparation delayed (CTA); FDA ODD in AML; financing delay led to receivable impairment H1 2026 |
| HY-106 (Methanobactin, ARBM-101) | NCE | Copper-selective injectable chelator, potentially intermittent dosing | Wilson's disease (EU/Turkey rights) | ArborMed (USD 2M upfront paid; ArborMed buy-back option pre-Phase 3) | First-in-human (healthy volunteers) planned 2026 |
Discontinued / divested programs (recent)
| Program | Date | Reason |
|---|---|---|
| HY-075 (oral liquid CV) | H1 2026 | Portfolio review / capital allocation (development previously paused pending partnering) |
| HY-091 (vulvar lichen sclerosus, with AFT) | H1 2026 | Portfolio review |
| XTRAZA US Phase 3 and US development | 2,026 | Recruitment rate and per-patient cost implied sub-target IRR |
| HY-038 (generic) | Divested Dec 2022/Jan 2023 to QliniQ | Non-core; transaction later restated as non-monetary exchange |
Financial Narrative
Basis: IFRS consolidated statements. FY2022 shown as restated (14 March 2024 restatement reversing EUR 1.0M HY-038 revenue). FY2021–FY2022 from FY2022 results release; FY2023–FY2024 from FY2024 results release; FY2025 from FY2025 results release. "Derived" items are analyst calculations from reported figures. Note that later releases occasionally reclassify prior-year items (e.g., FY2024 operating cash flow shown as -6,703 in the FY2024 release and -6,903 in the FY2025 release); the original-year figure is used unless stated.
Income statement
EPS notes: FY2022 restated EPS (-0.435) and FY2024/FY2025 EPS (-0.23) are as reported; FY2021 (-0.45) and FY2023 (-0.55) are derived from net loss over period-end share count (25.83M and 28.00M respectively) and should be treated as approximations. FY2021 "other operating expenses" of EUR 5.77M (largely one-off, linked to the Alter Pharma renegotiation era) depressed FY2021 EBIT; FY2021 SG&A presentation differs between tables in the FY2022 release.
Margins and growth
Revenue CAGR FY2021–FY2025 (derived): 23.5% (EUR 3.10M → EUR 7.21M). Using total operating income: 26.2%.
Commentary. The P&L shows three phases. (1) FY2021–FY2023: rising R&D investment (EUR 5.1M → EUR 14.4M, including a USD 2M Vaneltix R&D funding expensed in 2023) against stagnant, milestone-driven revenue, pushing net losses to a peak of EUR 15.4M. (2) FY2024 inflection: revenue quadrupled to EUR 8.5M on the Combogesic IV US launch milestone, first meaningful royalties (Maxigesic IV, Podofilox) and Valacyclovir upfront/regulatory payments, while R&D phasing fell 29%; net loss more than halved to EUR 6.3M despite EUR 2.2M of legal/forensic costs. (3) FY2025 consolidation: royalties +15% but milestone normalisation cut revenue 15%; G&A fell on lower legal costs while R&D rose 10% on headcount; net loss flat at EUR 6.3M. Gross margins are structurally ~95% because revenue is royalty-based; the relevant profitability lever is operating expense versus royalty scale. H1 2026 extended the improvement (net loss EUR 1.9M vs EUR 3.6M), helped by milestone income and a 16% R&D reduction from project phasing — partly timing rather than structural.
Balance sheet
Notes: The company states it has "no financial debt"; borrowings are IFRS 16 lease liabilities (office, lab equipment, cars). FY2021 other financial liabilities included shareholder loans repaid in 2022 (EUR 9.28M including interest). FY2022 equity and assets are restated (-EUR 1.0M). At 30 June 2026: cash EUR 8,735k, equity EUR 24,943k (H1 2026 release).
Commentary. Hyloris has funded EUR ~65M of cumulative losses since the 2020 IPO from IPO proceeds and the 2022 EUR 15M placement, without debt. Cash has declined every year (EUR 64.4M at end-2020 → EUR 13.8M at end-2025 → EUR 8.7M at mid-2026). Intangibles rose in FY2025 on in-licensing (including the USD 2M ArborMed upfront). Equity-accounted investees reflect FHP BV and, from 2025, Kuvatris.
Cash flow: notes and sources
Notes: FY2023 net change in cash was cushioned by EUR 10.0M of matured financial investments. FY2025 investing outflow of EUR 2.1M mainly reflects the Kuvatris equity investment (EUR 1.9M). H1 2026 cash decline: EUR 5.0M in six months.
Ratios
ROIC: negative and not meaningful (negative NOPAT; one vendor computes -45.7% TTM). Net debt/EBITDA and interest coverage: not meaningful (net cash, negative EBITDA, negligible interest). Cash conversion cycle: not meaningful/not publicly disclosed (royalty model, inventory EUR 52k at end-2025).
Ratio commentary. Returns are deeply negative but improving from the FY2023 trough. Liquidity ratios appear comfortable on a current-ratio basis but mask the absolute cash constraint: at the H1 2026 burn rate (~EUR 10M annualised before new milestones), end-June 2026 cash of EUR 8.7M covers less than a year without additional partnering inflows, which is why management cites expected out-licensing proceeds, R&D phasing flexibility and a CEO comfort letter.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Royalties (EUR K) | — | 4,901 | 5,649 |
Milestones (EUR K) | — | 3,557 | 1,353 |
Product sales (EUR K) | — | 0 | 205 |
Total revenue (EUR K) | 2,087 | 8,458 | 7,207 |
Other operating income (EUR K) | 2,127 | 1,584 | 1,626 |
Total operating income (EUR K) | 4,214 | 10,043 | 8,832 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
Royalties YoY growth (%) | — | 15 |
Milestones YoY growth (%) | — | -62 |
Royalties share of revenue (%) | 57.9 | 78.4 |
Milestones share of revenue (%) | 42.1 | 18.8 |
Product sales share of revenue (%) | 0 | 2.8 |
Revenue by Segment (Half-Yearly)
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Revenue (EUR K) | 3,018 | 4,696 |
Royalties (EUR K, H1 2025 rounded) | 2,900 | 2,917 |
Other operating income (EUR K) | 765 | 877 |
Total operating income (EUR K) | 3,784 | 5,573 |
Entity / Investee Details
| Entity / investee | Nature | Relevance |
|---|---|---|
Hyloris Pharmaceuticals SA | Parent, Liège | Listed holding/operating company |
Subsidiaries | Not detailed in sources reviewed (consolidated "Group" referenced) | Not publicly disclosed in reviewed documents |
FHP BV | Equity-accounted joint venture with Maatschap Purna and others | Miconazole-Domiphen Bromide program; carrying value EUR 2.7M (FY2024), impairment EUR 972k in 2024 reversed in 2025 |
Kuvatris Therapeutics Inc. | Equity-accounted investee (just under 20%) | Suramin IV; USD 1.6M equity investment |
Pleco Therapeutics BV | Other financial asset (loan converted to shares, EUR 1.0M) | PTX-252 (HY-086); EUR 474k receivable impairment in H1 2026 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (EUR K) | 3,096 | 1,951 | 2,087 | 8,458 | 7,207 |
Other operating income (EUR K) | 389 | 315 | 2,127 | 1,584 | 1,626 |
Total operating income (EUR K) | 3,485 | 2,266 | 4,214 | 10,043 | 8,832 |
Cost of sales (EUR K) | -107 | -94 | -93 | -227 | -379 |
Gross profit (EUR K, derived) | 2,989 | 1,857 | 1,994 | 8,231 | 6,828 |
R&D expenses (EUR K) | -5,056 | -10,151 | -14,421 | -10,265 | -11,281 |
G&A expenses (EUR K) | -2,900 | -3,517 | -5,546 | -5,627 | -4,882 |
Operating profit / EBIT (EUR K) | -10,541 | -11,638 | -15,993 | -7,130 | -6,808 |
D&A and impairments (EUR K) | 137 | 196 | 349 | 648 | 919 |
EBITDA (EUR K, derived) | -10,404 | -11,442 | -15,644 | -6,482 | -5,889 |
Pre-tax income (EUR K) | -11,282 | -11,766 | -15,380 | -6,342 | -6,707 |
Net income (EUR K) | -11,579 | -11,770 | -15,380 | -6,342 | -6,334 |
EPS basic (EUR) | -0.45 | -0.435 | -0.55 | -0.23 | -0.23 |
EPS diluted (EUR) | -0.45 | -0.435 | -0.55 | -0.23 | -0.23 |
Dividends per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue YoY growth (%) | — | -37.0 | 7.0 | 305.3 | -14.8 |
Gross margin (%) | 96.5 | 95.2 | 95.5 | 97.3 | 94.7 |
Operating margin (%) | -340.5 | -596.5 | -766.3 | -84.3 | -94.5 |
EBITDA margin (%) | -336.0 | -586.5 | -749.6 | -76.6 | -81.7 |
Net margin (%) | -374.0 | -603.3 | -737.0 | -75.0 | -87.9 |
R&D as % of revenue (%) | 163.3 | 520.3 | 691.0 | 121.4 | 156.5 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (EUR K) | 63,444 | 60,864 | 47,681 | 41,335 | 33,357 |
Cash and cash equivalents (EUR K) | 50,012 | 43,457 | 30,406 | 23,594 | 13,775 |
Lease borrowings short-term (EUR K) | 65 | 138 | 241 | 326 | 364 |
Lease borrowings long-term (EUR K) | 109 | 747 | 1,510 | 1,489 | 1,246 |
Total lease borrowings (EUR K) | 174 | 885 | 1,751 | 1,815 | 1,610 |
Other financial liabilities current (EUR K) | 11,815 | 3,212 | 3,200 | 3,000 | 0 |
Net debt (lease borrowings minus cash, EUR K) | -49,838 | -42,572 | -28,655 | -21,779 | -12,165 |
Total equity (EUR K) | 48,056 | 54,045 | 39,069 | 32,143 | 26,475 |
Goodwill (EUR K) | 0 | 0 | 0 | 0 | 0 |
Intangible assets (EUR K) | 2,944 | 3,607 | 3,828 | 3,838 | 5,689 |
Equity-accounted investees (EUR K) | 4,079 | 3,948 | 3,801 | 2,748 | 2,543 |
Working capital (EUR K, derived) | 38,981 | 44,029 | 28,549 | 22,545 | 14,825 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (EUR K) | -11,250 | -13,154 | -12,808 | -6,703 | -6,994 |
Capex PP&E (EUR K) | -107 | -101 | -298 | -29 | -4 |
Capex intangibles (EUR K) | -954 | -638 | -452 | -268 | -625 |
Free cash flow (EUR K, derived) | -12,311 | -13,893 | -13,558 | -7,000 | -7,623 |
Equity raised net (EUR K) | 0 | 17,169 | 0 | 0 | 0 |
Dividends paid (EUR K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (EUR K) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (EUR K) | -14,387 | -6,555 | -3,051 | -6,812 | -9,550 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%, on average equity; FY2021 on year-end) | -24.1 | -23.1 | -33.0 | -17.8 | -21.6 |
ROA (%, on average assets; FY2021 on year-end) | -18.3 | -18.9 | -28.3 | -14.2 | -17.0 |
Current ratio (x) | 3.60 | 8.63 | 5.22 | 4.15 | 3.89 |
Debt to equity (lease debt, x) | 0.004 | 0.016 | 0.045 | 0.056 | 0.061 |
Asset turnover (x) | 0.05 | 0.03 | 0.04 | 0.19 | 0.19 |
Revenue by Region
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (EUR K) | 2,087 | 8,458 | 7,207 |
Products
| Product | Principal revenue geographies | Evidence |
|---|---|---|
Sotalol IV | United States only | AltaThera US commercialisation |
Podofilox Gel | United States only | Padagis; US-manufactured |
TXA RTU | United States (Avenacy, launched H1 2026), Switzerland (launched H1 2026), Europe (Orion, registrations ongoing) | FY2025 and H1 2026 releases |
Maxigesic IV | South Korea (historically the highest-selling country per FY2024 release), Europe (launched from 2021), United States (Hikma since Feb 2024; royalties subject to cumulative sales threshold per FY2024 release), Canada, Brazil, Asia; China and Japan pending registration | FY2024/FY2025 releases; Jul and Sep 2026 releases |
Data Point Details
| Data point | Value | Source |
|---|---|---|
Last close (16 Oct 2026) | EUR 4.28 (+4.65% on day; intraday range 3.69–4.29) | Company share page |
Market capitalisation | EUR 119.8M | Company share page |
Performance year-to-date 2026 | -40.2% | Company share page |
Performance over last full year | -29.73% | Company share page |
Performance 1 month | -3.54% | Company share page |
Since IPO (EUR 10.75, Jun 2020) | -60.2% (derived) | Euronext IPO release; derived |
52-week range (as of May 2026) | EUR 4.51–8.40 (since breached to 3.69 low in Oct 2026) | Investing.com |
Average daily volume (3m, May 2026) | ~7,150 shares | Investing.com |
Share Count (millions) and Capital Markets Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Shares outstanding year-end (millions) | 25.83 | 28.00 | 28.00 | 28.00 | 28.00 |
Share capital (EUR K) | 129 | 140 | 140 | 140 | 140 |
Valuation Multiples
| Multiple | Hyloris | Basis |
|---|---|---|
P/E | Not meaningful (loss-making; EPS FY2025 -0.23) | — |
EV (EUR Mn) | ~112.6 | Market cap 119.8 less cash 8.7 plus leases ~1.5 (30 Jun 2026) |
EV/Sales FY2025 | ~15.6x | Revenue EUR 7.21M |
EV/Sales TTM (H2 2025 + H1 2026) | ~12.7x | TTM revenue EUR 8.89M (derived) |
EV/EBITDA | Not meaningful (negative EBITDA ≈ -EUR 5.9M FY2025) | — |
P/B | ~4.8x | Equity EUR 24.9M (30 Jun 2026) |
Peer reference | Eton Pharmaceuticals ~16x TTM sales (market cap USD 1.70B; TTM revenue USD 105.6M, StockAnalysis, Aug 2026) | Profitable, growing peer |
Analyst Ratings & Targets
| Broker | Analyst | Rating (date per company site) |
|---|---|---|
Degroof Petercam | David Seynnaeve | Buy (21 Mar 2025) |
Kepler Cheuvreux | Christophe Dombu | Buy (21 Mar 2025) |
KBC Securities | Jacob Mekhael | Hold (21 Mar 2025) |
Van Lanschot Kempen | Suzanne van Voorthuizen | Under review (21 Mar 2025) |
Analyst Conclusions
Management guidance (H1 2026 release)
Submissions for Aspirin IV and Dofetilide IV in H2 2026; End-of-Phase 2 for Alenura in H2 2026; HY-094 Phase 3 advancement; Metolazone IV, Milrinone ER progress; definition of the US cardiovascular commercialisation strategy (licensing or other partnerships); continued disciplined execution and governance. No quantitative financial guidance.
Consensus expectations
Two to four sell-side analysts; aggregators show break-even expectations around 2026–2027 and steep revenue ramps (MarketScreener FY2027E EUR 65.4M), implying large licensing milestones — high uncertainty and not company-endorsed.
Bull case
-
Royalty compounding plus new territories: Maxigesic/Combogesic IV (US promotion from late Q2 2026, China via Tongde, Japan via Mikasa) and TXA RTU (US, Switzerland, Europe via Orion) could lift recurring revenue materially above FY2025's EUR 5.9M.
-
CV portfolio monetisation: two positive pivotal CV assets (Dofetilide IV, Aspirin IV) with FDA alignment provide a credible package for a US licensing deal with upfront payments that would solve the funding question.
-
Asymmetric NCE optionality: a Suramin IV PRV (Hyloris >50% of net proceeds) or HY-094 Phase 3 success could each be worth a large fraction of the EUR ~120M market cap.
Bear case
-
Funding gap: EUR 8.7M cash against ~EUR 10M annual burn means a near-term dilutive raise or reliance on the CEO comfort letter unless partnering inflows arrive on time.
-
Governance/legal overhang: the October 2026 authorities' visit revives the 2024 QliniQ affair; possible sanctions, management distraction, and a persistent valuation discount.
-
Execution slippage: repeated delays (Dofetilide filing, Valacyclovir CRL, Metolazone, Suramin) and program cuts (XTRAZA US) suggest timelines and consensus revenue ramps are too optimistic.
Key catalysts and monitorables (next 12 months)
| Catalyst | Expected timing |
|---|---|
| Dofetilide IV US NDA submission | H2 2026 |
| Aspirin IV US submission (and EU) | H2 2026 |
| US cardiovascular portfolio partnering decision/deal | 2026–2027 (no date) |
| Alenura End-of-Phase 2 FDA meeting | H2 2026 |
| Outcome of authorities' investigation; any FSMA action | Unknown |
| Atomoxetine Oral Liquid FDA action (Rosemont) | 2026–2027 (PDUFA not disclosed) |
| Valacyclovir resubmission after CDMO remediation/second source | Into 2027 |
| HY-088 European filing confirmation | Overdue vs late H1 2026 plan |
| Combogesic IV US royalty trajectory and Hikma promotion | Quarterly via partner disclosures |
| FY2026 results | 25 Mar 2027 |
| Financing announcement (equity, partnership, use of CEO support) | Any time |
Analyst verdict
Hyloris has largely delivered on the operational promise of its model: it has turned a reformulation pipeline into four partnered commercial products, a royalty line that grew 15% in FY2025, two positive pivotal cardiovascular assets with FDA alignment, and an unusually active licensing cadence that now reaches China and Japan for Maxigesic IV. H1 2026 showed the best half-year loss since the 2020 IPO, and the asset-light structure keeps gross margins near 95% and the balance sheet debt-free.
The investment case, however, is constrained by three factors that dominate the fundamentals. First, liquidity: EUR 8.7M of cash at mid-2026 against an underlying burn near EUR 10M per year makes the next twelve months a race between partnering inflows and dilution; the explicit reliance on a CEO comfort letter in the going-concern assessment is a telling signal. Second, governance: the 2024 FSMA warning, trading suspension, restatement, serial audit qualifications and now an authorities' document request in October 2026 impose a credibility discount that no amount of pipeline news has yet offset, as reflected in a share price 60% below the IPO and 40% down year-to-date. Third, scale: royalties of EUR 5.6M remain far below an operating cost base of ~EUR 15M, so profitability depends on lumpy milestones and an as-yet-unannounced US cardiovascular deal.
At ~EUR 113M EV (~13x TTM revenue), the market is pricing some, but not full, success. The stock is best characterised as a high-risk, catalyst-driven special situation: a credible US cardiovascular licensing deal with meaningful upfront cash, clean resolution of the regulatory inquiry, or Suramin PRV progress could re-rate it sharply, while a discounted equity raise or adverse regulatory outcome would likely reset it lower. Position sizing should reflect binary risk; the verdict is speculative, event-driven — monitor funding and governance resolution before conviction.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education | Age |
|---|---|---|---|---|---|
Stijn Van Rompay (via SVR Management BV) | CEO & co-founder | Co-founder 2012; CEO; co-CEO Jul 2024–Nov 2025; sole CEO since 19 Nov 2025 | Co-founder/CEO Alter Pharma; co-CEO Uteron Pharma; CFO then CEO Docpharma | Master's in Applied Economics (University of Antwerp); honorary doctorate (Long Island University) | Born 1975 per Beursgenoten (not company-verified) |
Thomas Jacobsen (via Jacobsen Management BV) | Chief Business Development Officer & co-founder | Co-founder 2012; co-CEO mid-2024 to Nov 2025 | Co-founder Alter Pharma; Docpharma (out-licensing); Alternova | Master's in Pharmacy (University of Copenhagen); business degree (Copenhagen Business School) | Not publicly disclosed (vendors cite 1974/1975) |
Christophe Maréchal (via CMM&C SRL) | CFO | Since Dec 2024 | Senior finance roles at Orange, AGC, Mithra Pharmaceuticals; >30 years experience | MBA/Commercial Engineering (University of Liège); econometrics studies (Tilburg) | — |
Dr. Dietmar Aichhorn | COO | — | Sandoz, Mylan, Innovacell, ViraTherapeutics, Polpharma Biologics (head clinical development roles) | Master's in Chemistry (Kepler University Linz); doctorate (Vienna University of Economics and Business) | — |
Ann De Jaeger (via Impact WITH Empathy BV) | Chief Legal Officer & General Secretary to the Board | Since Aug 2025 | Tate & Lyle, Barco, Alpro, Danone, What's Cooking Group | Master of Law (Ghent); business law (Antwerp); IMD/MIT/Vlerick; certified board director | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Independence | Notes |
|---|---|---|---|
Vincent Van Dessel (Sybefica Invest SRL) | Chairman since Jun 2026 | Independent | Former Chairman & CEO Euronext Brussels; Chairman of VFB (Belgian retail investors' federation) since Jan 2025 |
Stefan Yee | Non-executive director (Chairman until Jun 2026; website still lists "Chairman") | Not stated as independent | PE investor (PE Group/Arteva Capital); ex-KPMG, Linklaters; former director of Docpharma, Uteron |
Leon Van Rompay | Non-executive director | Non-independent | Founder/CEO Docpharma; former Zambon board member; >40 years pharma |
Dr. Mélanie Mestdagt (Biofinance Consulting BV) | Non-executive director since Jun 2025 (3-year term) | Independent | CEO EyeD Pharma and UniD Manufacturing; VP BioWin |
Dr. Revital Rattenbach (IRYL Partners SAS) | Non-executive director; Chair of Product Selection Committee | Independent | Founding CEO 4P-Pharma; board member Biosenic |
Stijn Van Rompay | Executive director (CEO) | Executive | — |
Thomas Jacobsen | Board membership as of 2026 not confirmed in company sources (listed as board member by data vendors) | Executive | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
8 Jul 2024 | Thomas Jacobsen appointed co-CEO; CFO Jean-Luc Vandebroek and CLO Koenraad Van der Elst to leave | Board decisions following forensic review of QliniQ transactions and FSMA warning |
9 Dec 2024 | Christophe Maréchal appointed CFO | Replacement of departed CFO |
Jun 2025 | Marc Foidart resigns; Biofinance Consulting (Mestdagt) appointed | AGM board renewal |
Aug 2025 | Ann De Jaeger appointed CLO | Fills CLO vacancy |
19 Nov 2025 | Stijn Van Rompay sole CEO; Jacobsen returns to CBDO | External governance review; the 2024 plan to transition to an independent CEO was not pursued |
9 Jun 2026 | Vincent Van Dessel appointed Chairman | Succeeds Stefan Yee as Chair |
Major Shareholders
| Holder | Shares / stake | Source & date | Comment |
|---|---|---|---|
Stijn Van Rompay (CEO) | ~10.27M shares (~36.7%) | Simply Wall St (May 2025) | Conflicts with Beursgenoten (7,743,067 shares; 27.65%) and last FSMA notification (26.42%, Jul 2020) — discrepancy noted; company's own Mar 2026 chart not machine-readable |
Thomas Jacobsen (CBDO) | ~3.86M shares (~13.8%) | Simply Wall St (May 2025) | FSMA notification Jun 2020: 13.43% |
Bart Versluys (Scorpiaux BV, Versluys Bouwgroep NV) | 2,119,774 (7.57%) | Transparency notification, threshold crossed 9 Jan 2026 | Only recent formal notification |
Nick Reunbrouck | 1,610,184 (6.29% at the time) | FSMA notification Jun 2020 | Possibly outdated |
Pieter Van Rompay | 915,000 (3.58% at the time) | FSMA notification Jun 2020 | Possibly outdated |
Saffelberg Investments NV | ~3% | Transparency notification 29 Jun 2022; vendor 3.07% | — |
Edward Maloney | ~1.6% | Simply Wall St (older snapshot) | — |
Mandarine Gestion | 77,000 (0.29%) | Simply Wall St (older snapshot) | Institutional |
Degroof Petercam Asset Management | 15,000 (0.05%) | Simply Wall St (May 2025) | Institutional |
Dimensional Fund Advisors | 5,164 (0.02%) | Simply Wall St (May 2025) | Institutional |
Competitive Landscape
Competitors by Segment
| Area | Competitor(s) | Relationship to Hyloris |
|---|---|---|
Value-added medicines / reformulation platforms | Eton Pharmaceuticals (US, paediatric/rare reformulations); Azurity Pharmaceuticals (US, private, oral liquids); AFT Pharmaceuticals (also partner) | Compete for in-licensing deals and 505(b)(2) niches |
Non-opioid hospital analgesia | Pacira BioSciences (EXPAREL); Heron Therapeutics (ZYNRELEF); B. Braun and Fresenius Kabi (IV paracetamol); Vertex (oral non-opioid suzetrigine) | Compete with Maxigesic/Combogesic IV for post-operative protocols |
Antiarrhythmics | Pfizer (Tikosyn oral dofetilide) and generic dofetilide makers; amiodarone IV suppliers | Dofetilide IV/Sotalol IV positioned against oral initiation and IV amiodarone |
IV iron | CSL Vifor (ferric carboxymaltose), Pharmacosmos (ferric derisomaltose), Daiichi Sankyo/American Regent (US) | HY-094 must differentiate on single-dose tolerability |
IV PPI | Pfizer (Protonix IV) and lyophilised pantoprazole generics | Pantoprazole IV RTU targets convenience share |
Generic injectables (TXA) | Fresenius Kabi, Hikma, Exela and others in TXA IV | TXA RTU competes on ready-to-use format |
ADHD liquids | Tris Pharma and other liquid stimulant/non-stimulant suppliers | Atomoxetine Oral Liquid niche |
Peer Comparison FY2025
| Company | FY | Revenue | Revenue growth (%) | Gross margin (%) | Operating/net margin | R&D intensity (%) |
|---|---|---|---|---|---|---|
Hyloris Pharmaceuticals | FY2025 (Dec) | EUR 7.2M | -15 | 94.7 | Operating margin -94.5% | 156.5 |
Pacira BioSciences | FY2025 (Dec) | USD 726.4M | 4 | ~81 (company commentary) | GAAP net income USD 7.0M (~1.0% net margin) | 16.1 (R&D USD 117.3M) |
Eton Pharmaceuticals | FY2025 (Dec) | USD 79.9M | 105 | 53.5 (gross profit USD 42.7M) | Adjusted EBITDA USD 15.8M (~19.8%) | — |
AFT Pharmaceuticals | FY2026 (Mar) | NZD 254.7M | 22 | 43.4 | Operating margin 9.6% | 3.9 (R&D NZD 9.8M) |



